

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for

Washington, DC 20231.

Practitioner's Docket No. MBIO99-057CP2RCEM **PATENT**

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office

on ____June 2, 2006 Signature

Sean Hunziker Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

Submitted herewith:

Amendment Transmittal Amendment and Reponse

(2 pages-in duplicate) (12 pages)

Total

Pages (17 pages) (Including this cover sheet)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

REGEIVED CENTRAL FAX CENTER JUN 0 2 2006

Practitioner's Docket No. MBIO99-057CP2RCEM

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Busfield, Samantha J., et al

Application No.:

09/503,387

Group No.:

1644

Filed:

February 14, 2000

Examiner:

Huynh, Phuong N.

For:

GLYCOPROTEIN VI AND USES THEREOF

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

AMENDMENT TRANSMITTAL

1. Transmitted herewith for this application is/are:

- a. This Amendment Transmittal which includes a request for extension of time (3 pages, in duplicate); and
- b. Amendment and Response (12 pages).

STATUS

2. Applicant is other than a small entity.

06/05/2006 AKELECH1 00000087 501668 09503387

01 FC:1253

1020.00 DA

	CERTIFICATION UNDER 37 C	.F.R. SECT	FIONS 1.8(a) and 1.10*						
I hereby	certify that, on the date shown below, this corresponden	ce is being:							
	MAD deposited with the United States Postal Service in an enfor Patents, P.O. Box 1450, Alexandria, VA 22313-14 37 C.F.R. SECTION 1.8(a)	ressed to the Mail Stop Amendment, Commissioner 37 C.F.R. SECTION 1.10*							
	with sufficient postage as first class mail.	Þ	as "Express Mail Post Office to Addressee" Mailing Label No.						
图	TRANSA transmitted by facsimile to the Patent and Trademark C		an Alman						
Date:	Signature Sean Hunziker June 2, 2006 (type or print name of person certifying)								

*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Page 1 of 2)

Practitioner's Docket No. MBIO99-057CP2RCEM



PETITION FOR EXTENSION OF TIME

3.	The proceedings	herein are for	r a patent a	pplication	and the	provisions	s of 37	C.F.R.	1.136	apply.	
Applica	ant petitions for a	n extension of	f time under	r 37 C.F.R	R. 1.136	(fees: 37	C.F.R.	1.17(a)	(1)-(3))	for a	
three m	onth extension:										
				Fee:	\$ 1	,020.00					

If an additional extension of time is required, please consider this a petition therefor.

Extension fee due with this request

FEE PAYMENT

4. Charge Account No. 501668 the sum of \$1,020.00 (which includes the \$1,020.00 extension fee and the \$0.00 additional fee for claims). A duplicate of this transmittal is attached.

FEE DEFICIENCY

- 5. If any additional extension and/or fee is required, charge Account No. 501668. If any additional fee for claims is required, charge Account No. 501668.
- 6. Correspondence Address
 Direct all future correspondence to:

Customer Number 30405

OR

Intellectual Property Department
MILLENNIUM PHARMACEUTICALS, INC.
40 Landsdowne Street
Cambridge, MA 02139

June 2, 2006

MILLENNIUM BHARMACEUTICALS, INC.

\$1,020.00

Βv

Mario Cloutier Registration No. 57,225 40 Landsdowne Street Cambridge, MA 02139 Telephone - 617-577-3522 Facsimile - 617-551-8820

ucshmic - 017 551 6626

CENTRAL FAX SENTER JUN U 2 2006

Practitioner's Docket No. MBIO99-057CP2RCEM

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Busfield, Samantha J., et al

Application No.:

09/503,387

Group No.:

1644

Filed:

February 14, 2000

Examiner:

Huynh, Phuong N.

For:

GLYCOPROTEIN VI AND USES THEREOF

Mail Stop Amendment **Commissioner for Patents** P.O. Box 1450 Alexandria, VA 22313-1450

AMENDMENT AND RESPONSE

Sir,

In response to the Office Action mailed December 19, 2005, please enter and consider the remarks below intended to put this application into form for allowance.

The Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 8 of this paper.

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10* I hereby certify that, on the date shown below, this correspondence is being: **MAILING** deposited with the United States Postal Service in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. 37 C.F.R. SECTION 1.10* 37 C.F.R. SECTION 1.8(a) with sufficient postage as first class mail. as "Express Mail Post Office to Addressee" Mailing Label No. TRANSMISSION × transmitted by facsimile to the Patent and Trademark Office Signature Sean Hunziker Date: June 2, 2006 (type or print name of person certifying)

*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Page 1 of 12)